EP0546590B1 - Nachweis von amplifizierten Nukleinsäuren unter Verwendung von sekundären wasserlöschlichen Helper-Oligonukleotiden und Testsatz dafür - Google Patents

Nachweis von amplifizierten Nukleinsäuren unter Verwendung von sekundären wasserlöschlichen Helper-Oligonukleotiden und Testsatz dafür Download PDF

Info

Publication number
EP0546590B1
EP0546590B1 EP92203000A EP92203000A EP0546590B1 EP 0546590 B1 EP0546590 B1 EP 0546590B1 EP 92203000 A EP92203000 A EP 92203000A EP 92203000 A EP92203000 A EP 92203000A EP 0546590 B1 EP0546590 B1 EP 0546590B1
Authority
EP
European Patent Office
Prior art keywords
nucleic acid
target nucleic
capture probe
oligonucleotide
complementary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP92203000A
Other languages
English (en)
French (fr)
Other versions
EP0546590A1 (de
Inventor
Annie Liu C/O Eastman Kodak Co. Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ortho Clinical Diagnostics Inc
Original Assignee
Johnson and Johnson Clinical Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson and Johnson Clinical Diagnostics Inc filed Critical Johnson and Johnson Clinical Diagnostics Inc
Publication of EP0546590A1 publication Critical patent/EP0546590A1/de
Application granted granted Critical
Publication of EP0546590B1 publication Critical patent/EP0546590B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6832—Enhancement of hybridisation reaction
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Definitions

  • This invention relates to a method for amplifying and detecting nucleic acids of interest. It also relates to a test kit comprising a capture probe and secondary oligonucleotides useful for improved capture hybridization efficiency.
  • Nucleic acid probe technology has developed rapidly in recent years as researchers have discovered its value for detection of various diseases, organisms or genetic features which are present in small quantities in a human or animal test sample.
  • the use of probes is based upon the concept of complementarity such that complementary strands of nucleotides can and will, under proper conditions, hybridize to form a double stranded product.
  • DNA inherently has two strands bound together by hydrogen bonds between complementary nucleotides (which are also known as nucleotide pairs).
  • RNA while being single stranded, also can hybridize with a complementary strand of nucleotides.
  • Hybridization of complementary strands is a central feature of what are known as hybridization assays (also known as genetic probe assays).
  • hybridization assays also known as genetic probe assays.
  • a sequence of a nucleic acid of interest identified as a target nucleic acid
  • probes oligonucleotides
  • the probe usually is labeled in some fashion so that its detection also signals the presence of the hybridized product of probe and target nucleic acid. If the target nucleic acid is then unique to a particular organism, viral infection or genetic feature, the presence of the organism, virus or genetic feature can then readily be determined.
  • the target nucleic acid (single strand form) is insolubilized on a solid surface (such as a nitrocellulose membrane) to prevent undesirable hybridization with oligonucleotides other than probes.
  • a solid surface such as a nitrocellulose membrane
  • the target nucleic acid may be captured using another oligonucleotide which is immobilized in some manner, for example on a membrane as described in US-A-4,727,019.
  • the oligonucleotide is immobilized on polymeric particles which are embedded within a porous matrix (for example as described in EP-A-0 200 381).
  • EP-A-0 318 245 describes the need to improve the kinetics of hybridization between a water-soluble probe (such as a detection probe) and a long target nucleic acid in solution hybridization assays. This need is allegedly met using "helper" oligonucleotides which, it is believed, reorder the secondary and tertiary structure of the target nucleic acid in solution. These oligonucleotides hybridize with the target nucleic acid in regions other than that where the detection probe hybridizes.
  • the oligonucleotide attached to a water-insoluble support is usually very small in relation to the size of the support.
  • the length of the oligonucleotide is so short that it extends only a very short distance from the surface of the support. Thus, steric hindrance is believed responsible for slow hybridization rates between the capture probe and the target nucleic acid.
  • the present invention provides a way to improve hybridization of relatively short target nucleic acids with relatively short capture probes which are covalently bound to water-insoluble supports.
  • the present invention comprises a method for the amplification and detection of a double-stranded nucleic acid comprising:
  • the invention also provides a kit for the amplification and detection of a target nucleic acid comprising a probe comprising an oligonucleotide complementary to a first sequence of the target nucleic acid, and one or more water-soluble, distinct secondary oligonucleotides, each of the secondary oligonucleotides being complementary to a sequence of the target nucleic acid other than the first sequence, the kit characterized wherein the probe is a water-insoluble capture probe which is not detectably labeled, and comprises a water-insoluble polymeric particle to which the probe oligonucleotide is attached, the oligonucleotide being from 15 to 20 nucleotides in length, and each of the secondary oligonucleotides has a length which is equal to or greater than the length of the capture probe oligonucleotide.
  • dNTP's is a generic term for the various nucleotide triphosphate units that make up a nucleic acid, and which can be incorporated onto the end of a nucleic acid by a polymerase. Typically they include dATP, dCTP, dGTP and dTTP, together with dUTP for RNA molecules.
  • the method and kit of this invention provides a means for rapid and sensitive detection of nucleic acids using known PCR procedures which are hereby improved in the detection step.
  • the improvement is achieved by using secondary oligonucleotides with the capture probe, all of which hybridize with the amplified target nucleic acid.
  • the assay provides advantages so that the capture probe is readily separated from unwanted materials because of the polymeric particles to which the capture oligonucleotide is covalently and directly attached. Separation can be readily achieved using filtration membranes, porous matrices, centrifugation and other separation techniques.
  • the capture probe can be attached in a suitable fashion to a nonporous particle which is readily contacted with an amplified target.
  • the secondary oligonucleotides be of a certain length, namely equal to or greater than the length of the capture oligonucleotide.
  • the capture oligonucleotide is from 15 to 20 nucleotides in length. This invention provides improved hybridization rates between target nucleic acid and capture probe.
  • the present invention is directed to the amplification and detection of one or more specific nucleic acid sequences present in one or more targeted nucleic acids in a test specimen.
  • Such specimens can include cellular or viral material, hair, body fluids or other materials containing genetic DNA or RNA which can be detected.
  • the present invention is especially useful for producing, in exponential quantities relative to the number of reaction steps involved, at least one specific nucleic acid sequence.
  • the product will be a discrete nucleic acid duplex with termini corresponding to the ends of the specific primers employed. Any source of nucleic acid, purified or not, can be utilized as the starting material. A mixture of nucleic acids can be employed if desired.
  • the sequence to be duplicated can be a fragment of the entire nucleic acid.
  • Nucleic acids to be detected can be obtained from various sources including plasmids, naturally occurring DNA or RNA from any source (such as bacteria, yeast, viruses, plants and higher animals, humans). It may be extracted from various tissues including blood, peripheral blood mononuclear cells (PBMC), tissue material or other sources known in the art using known procedures.
  • PBMC peripheral blood mononuclear cells
  • the present invention is particularly useful for the amplification and detection of nucleic acid sequences found in genomic DNA, bacterial DNA, fungal DNA, viral RNA, or DNA or RNA found in bacterial or viral infected cells.
  • the method described herein can be used to provide the detection or characterization of specific nucleic acid sequences associated with infectious diseases, genetic disorders or cellular disorders such as cancers. It may also be used in forensic investigations and DNA typing.
  • genetic diseases include specific deletions or mutations in genomic DNA from any organism, such as sickle cell anemia, cystic fibrosis, a-thalessemia, b-thalessemia and others readily apparent to one skilled in the art.
  • Human Leukocyte Antigen (HLA) can be categorized with the present invention.
  • Various infectious diseases can be diagnosed by the presence in a clinical sample of small quantities of specific DNA sequences characteristic of the organism, whether it be a yeast, bacterium or virus.
  • Such bacteria which can be detected include, but are not limited to, Salmonella, Streptococcal organisms, Chlamydial organisms, Gonococcal organisms, Mycobacterium tuberculosis , Mycobacterium ayium complex, Mycoplasma Haemophilus influenzae , Shigella and Listeria.
  • Viruses which are detectable include, but are not limited to, herpes, Epstein Barr virus, cytomegalovirus, human papilloma virus, hepatitis and retroviruses such as HTLV-I, HIV-I and HIV-II. Other detectable species would be readily apparent to one skilled in the art.
  • the amount of b-globin DNA can also be detected. The invention is particularly useful for the detection of the presence of viral DNA.
  • the target nucleic acid is less than 250-mer in length.
  • the term "mer” is used to refer to a single nucleotide.
  • the primer is preferably single stranded for maximum efficiency in amplification.
  • the primer is an oligodeoxyribonucleotide.
  • the exact size of each primer will vary depending upon the use contemplated, the complexity of the targeted sequence, reaction temperature and the source of the primer.
  • the primers used in this invention will have from 12 to 60 nucleotides, and preferably, they have from 18 to 45 nucleotides.
  • Primers, probe oligonucleotides and secondary oligonucleotides useful herein can be obtained from a number of sources or prepared using known techniques and equipment, including for example, an ABI DNA Synthesizer (available from Applied Biosystems) or a Biosearch 8600 Series or 8800 Series Synthesizer (available from Milligen-Biosearch, Inc.) and known methods for their use (for example as described in US-A-4,965,188. Naturally occurring primers isolated from biological sources are also useful (such as restriction endonuclease digests).
  • a “capture probe” is a water-insoluble material comprised of a solid polymeric particle (described below) to which is covalently attached an oligonucleotide which is substantially complementary to a "first" nucleic acid sequence of the targeted nucleic acid.
  • the oligonucleotide of the probes is of a critical length, that is from 15 to 20 nucleotides, in order to best detect single base mutations or deletions in a target nucleic acid.
  • thermostable DNA polymerases have been reported in the art, including those mentioned in US-A-4,965,188 and US-A-4,889,818. Particularly useful polymerases are those obtained from various Thermus bacterial species, such as Thermus aquaticus , Thermus thermophilus or Thermus flavus . Other useful thermostable polymerases are described in WO-A-89/06691.
  • the secondary oligonucleotides used in the practice of this invention generally have a length equal to or greater than that of the probe oligonucleotide. More specifically, the length is from 15 to 35 nucleotides. At least one secondary oligonucleotide is used in the invention, each of which is complementary to a distinct sequence of the target nucleic acid, and those distinct sequences are different from the "first" sequence to which the probe oligonucleotide is complementary.
  • a targeted nucleic acid can be obtained from any of a variety of sources. Generally, it is extracted in some manner to make it available for contact with the primers and other reaction materials. This usually means removing unwanted proteins and cellular matter from the specimen in a suitable manner. Various procedures are known in the art.
  • nucleic acid to be amplified or detected is usually in double stranded form, the two strands must be separated (that is, denatured) before priming can take place. Denaturing is accomplished using a heat treatment alone or in combination with any suitable other physical, chemical or enzymatic means as described in the art.
  • the denatured strands are then cooled to a second temperature which is generally in the range of from 55 to 70°C where priming and primer extension are carried out in the presence of the DNA polymerization reagents identified below.
  • the resulting double-stranded primer extension products are heated to denature the strands. Once the strands are separated, they are available as templates for forming additional primer extension products therewith.
  • thermostable DNA polymerase suitable deoxyribonucleotide-5'-triphosphates (for example, dATP, dCTP, dGTP and dTTP) and a suitable set of primers at the beginning of the first cycle.
  • suitable deoxyribonucleotide-5'-triphosphates for example, dATP, dCTP, dGTP and dTTP
  • a suitable set of primers at the beginning of the first cycle.
  • the amount of thermostable DNA polymerase to be used is known in the art.
  • the dNTP's and primers are present in amounts effective for DNA polymerization to occur, such amounts being known in the art.
  • Other reagents are also preferably present, including salts such as magnesium chloride, extenders such as gelatin or other water soluble or water dispersible colloids.
  • the reaction mixture is generally buffered to a pH of from 7 to 9 with pH of 8 being preferred using any of a number of suitable buffers known in the art.
  • the volume of the reaction mixture including the targeted nucleic acid is not critical, but with smaller volumes, heat can be transferred to and away more rapidly.
  • the reagents for polymerization can be added to the specimen containing targeted nucleic acid at any suitable time, as is known in the art.
  • the reagents can be added at several and various times during an amplification cycle. Workers skilled in the art would be able to design an acceptable protocol for reagent addition.
  • the newly synthesized hybridized product of the template and its complementary nucleic acid formed from the primer are used in subsequent steps of the method. They are then denatured by heating, and used as templates for further cycles of priming, extension and denaturation as is known in the art.
  • the time for each cycle can vary widely depending upon the equipment and reagents used. In a preferred embodiment, each cycle is 120 seconds or less. The cycle can be completed as often as needed to produce the desired quantity of the targeted nucleic acid.
  • the final primer extension products can be detected as described below.
  • the products are denatured a last time providing multiple copies of the strands of the targeted nucleic acid.
  • the amplification method of this invention is preferably conducted in a continuous, automated manner so that the reaction mixture is temperature cycled in a controlled manner for desired preset times.
  • a number of instruments have been developed for this purpose, as one of ordinary skill in the art would know.
  • Another instrument utilizes temperature cycling without a liquid handling system, and is also described in some detail in US-A-4,965,188 and EP-A-0 236 069.
  • this instrument includes a heat conducting container for holding a number of reaction tubes containing reaction mixture, a means for heating, cooling and temperature maintenance, and a computing means to generate signals to control the amplification sequence, changes in temperature and timing.
  • a preferred instrument for processing amplification reactions in a disposable chemical test pack is described in some detail in EP-402 994.
  • this instrument comprises a support surface for supporting a chemical test pack, pressure applicators supported above the surface for acting on the reaction pack to transfer fluids between adjacent chambers in the test pack, and means for operating the pressure applicators through a range of movement extending across the test pack.
  • EP-402 995 provides details of useful chemical test packs which can be processed using the instrument described in EP-402 994. Also described therein are means for heating and cooling the test pack at repeated intervals (that is, through cycles) appropriate for the method of the present invention.
  • the method of this invention can be used to advantage to rapidly detect a target nucleic acid which is present, for example, in an infectious agent. Once a desired amount of the target nucleic acid has been generated, it is detected by forming a water-insoluble, hybridization product of it with a capture probe which is not labeled.
  • the capture probe comprises a water-insoluble polymeric particle to which is covalently attached an oligonucleotide (15-20 nucleotides) which is complementary to a first sequence of the target nucleic acid.
  • the oligonucleotide can be directly attached through covalent bonds resulting from chemical reaction of the oligonucleotide and reactive groups on the particles.
  • a spacer group of some type can be attached to the particle or oligonucleotide prior to attachment.
  • One such useful spacer group and procedures for its use are described in US-A-4,914,210.
  • polymeric particles can be used in practicing this invention, including those prepared from naturally occurring or synthetically prepared polymers.
  • the particles are spherical in shape and have an average size (largest dimension) of from 0.01 to 10 mmeters, although the size, structural and spatial configurations are not critical.
  • Preferred particles have an average diameter of from 0.01 to 5 mmeters.
  • Many such particles are commercially available from a number of sources.
  • reagents and procedures for preparing such particles are well known, for example as described in EP-A-0 323 692.
  • the oligonucleotide is covalently attached to the surface of the particles using any of a number of reactive groups and reactions known in the art.
  • Reactive groups on the surface of the particles can be provided as part of the structure of the polymer, or added by coating or chemical treatment of an inert material.
  • suitable reactive groups including, but not limited to: carboxy, 2-substituted ethylsulfonyl, 2-substituted ethylcarbonyl, vinylsulfonyl, amino, sulfhydryl, vinylcarbonyl, epoxy, aldehyde, active halogen groups, hydrazide and active esters such as succinimidoxycarbonyl.
  • Particularly useful particulate carrier materials are polymeric beads described, for example, in EP-A-0 323 692 which are prepared from one or more ethylenically unsaturated polymerizable monomers having an active halogen group, activated 2-substituted ethylsulfonyl or vinylsulfonyl groups.
  • Other particularly useful particles having reactive carboxy groups are described in EP-A-0 466 220.
  • Useful homo- and copolymers include, but are not limited to: poly(styrene- co -acrylic acid) (70:30 molar ratio), poly( m & p -chloromethylstyrene), poly(styrene- co - m & p -chloromethylstyrene- co -2-hydroxyethyl acrylate) (67:30:3 molar ratio), poly[styrene- co - m & p -(2-chloroethylsulfonyl-methyl)styrene] (96:4 molar ratio), poly ⁇ styrene- co -N-[ m & p -(2-chloroethylsulfonylmethyl)phenyl]acrylamide ⁇ (99.3:0.7 molar ratio), poly( m & p -chloromethylstyrene- co -metharylic acid) (95:5
  • Forming a hybridization product of the amplified target nucleic acid and the capture probe can be accomplished by mixing the two materials under conventional conditions, such as a temperature in the range of from 40 to 45°C for a time of at least 5 minutes. Representative specific conditions are described in the example below.
  • the target nucleic acid is also hybridized with one or more distinct secondary oligonucleotides.
  • Each of these oligonucleotides is complementary to a distinct sequence of the target nucleic acid which is different from the first sequence noted above, and different from each other.
  • the length of these oligonucleotides is described above. They are generally unlabeled and water-soluble. Preferably two secondary oligonucleotides are used in the assay, but more can be used if desired.
  • the amplified target nucleic acid be contacted with the capture probe and secondary oligonucleotides substantially simultaneously.
  • the amount of secondary oligonucleotide can be widely varied, but preferably it is present at about the same concentration as the capture probe oligonucleotide.
  • the resulting hybridized product of amplified target nucleic acid, capture probe and secondary oligonucleotides can be detected in any suitable fashion which would be apparent to a skilled worker in the art.
  • detection requires that the hybridized product be separated from the other materials in the reaction medium. This can be done by any of a number of ways, including filtration, centrifugation or other suitable separation techniques.
  • Particularly useful separation means include microporous filtration membranes such as the polyamide membranes marketed by Pall Corp. They can be used uncoated or precoated with surfactants or other materials which facilitate fluid flow. Other types of filters can be used also.
  • the membrane or filter can be used as a separate article with suitable containers for collecting fluid and water-soluble materials.
  • the membranes are mounted as part of a test device.
  • test devices are known in the art including those described in US-A-3,825,410, US-A-3,888,629, US-A-3,970,429 and US-A-4,446,232. Particularly useful devices are described in US-A-4,921,677
  • the target nucleic acid can be detected using the capture probe which has been immobilized on a flat substrate, such as the microporous filtration membranes described above, or on thin polymeric films, uncoated papers or polymer coated papers, a number of which are known in the art, glass slides and other nonporous substrates readily apparent to one skilled in the art.
  • a flat substrate such as the microporous filtration membranes described above, or on thin polymeric films, uncoated papers or polymer coated papers, a number of which are known in the art, glass slides and other nonporous substrates readily apparent to one skilled in the art.
  • detection of the hybridized product can be accomplished using a detection probe which is complementary either to the capture probe or to still another sequence of the target nucleic acid (that is, a sequence other than those complementary to the capture probe and secondary oligonucleotides).
  • detection can be achieved using a detection probe complementary to at least one of the secondary oligonucleotides.
  • Useful enzymes include, glucose oxidase, peroxidases, uricase, alkaline phosphatase and others known in the art and can be attached to oligonucleotides using known procedures.
  • Substrates and reagents for providing a detectable colorimetric, fluorometric or chemiluminescent signal in the presence of a given enzyme label are well known, for example as described in US-A-4,994,373.
  • the label is a preferred enzyme such as a peroxidase
  • suitable dye-forming compositions are added to provide a detectable dye.
  • useful dye-providing reagents include tetramethylbenzidine and derivatives thereof, and leuco dyes, such as triarylimidazole leuco dyes (as described in US-A-4,089,747), or other compounds which react to provide a dye in the presence of peroxidase and hydrogen peroxide.
  • leuco dyes such as triarylimidazole leuco dyes (as described in US-A-4,089,747), or other compounds which react to provide a dye in the presence of peroxidase and hydrogen peroxide.
  • Particularly useful dye-providing compositions are described in EP-A-0 308 236.
  • Detection of the resulting signal can be achieved using suitable detection equipment and procedures which are well known. Certain probes may provide signals which are visible to the eye without the use of detection equipment.
  • one of the primers is labeled with a specific binding ligand such as biotin, an antibody or lectin.
  • the labeled primer provides (through amplification) an amplified target nucleic acid which has the specific binding ligand attached.
  • This amplified nucleic acid is detected using a detectably labeled receptor for specific binding ligand.
  • the receptor for example avidin, can be conjugated with an enzyme, or have a radioactive moiety which provides a detectable signal as noted above.
  • the amplified target nucleic acid can be detected by incorporating a radioisotope into the amplified product by using dNTPs in the primer extension which are labeled with a radioisotope.
  • a capture probe was composed of particles of poly(styrene- co -acrylic acid) (70:30 molar ratio, 2.1 mmeter average diameter) having covalently attached thereto an oligonucleotide having the following sequence which is complementary to a first sequence of the target nucleic acid:
  • the oligonucleotide was attached to the particles through "X", an aminotetraethylene glycol linker having 16 ethylene glycol units using the procedure described in US-A-4,914,210. More specifically, an aqueous suspension of the particles (1 ml, 30 mg solids) was centrifuged and the supernatant discarded. The particles were then resuspended in glass-distilled water (1 ml) by vigorous vortexing, followed by centrifugation and removal of the supernatant. The particles were then resuspended again in a solution (1 ml) of sodium chloride (3 normal) in methylimidazole buffer (0.2 molar, pH 7).
  • the reaction mixture was centrifuged and the supernatant removed.
  • the resulting particulate reagent was washed with the following fluids by centrifugation and pipetting off the supernatant between washings: a) three washings with glass-distilled water (1 ml each time), and b) three washings with a buffer solution (1 ml each time, pH 7.4) comprising sodium chloride (0.018 molar), sodium phosphate (1 mmolar) ethylenediaminetetraacetic acid (0.1 mmolar) and dodecyl sulfate (0.5%) and which had been prewarmed to 70°C.
  • the reagents were resuspended in glass-distilled water to a final volume of 1 ml to make a 3% dispersion. It was stored at 4°C until its use.
  • a leuco dye composition was prepared containing 2-(4-hydroxy-3,5-dimethoxyphenyl)-4,5-bis(4-methoxyphenyl)imidazole as follows: Solid leuco dye (to make a 0.1% solution) was dissolved in a solution of poly(vinylpyrrolidone) (20%) in sodium phosphate buffer (5 mmolar). This solution was then added to a solution of hydrogen peroxide (10 mmolar), 4'-hydroxyacetanilide electron transfer agent (5 mmolar) and diethylenetriaminepentaacetic acid chelating agent (10 mmolar) in sodium phosphate buffer to produce a final concentration of 1% polymer and 0.005% leuco dye.
  • a DNA polymerase was used during amplification which was isolated from Thermus aquaticus using standard procedures, and which had an activity of 4 units/ml).
  • a "unit” is defined as the amount of enzyme activity required to incorporate 10 nmoles of total nucleotides (dNTP's) into an extending nucleic acid chain in 30 minutes at 74° C.
  • the target nucleic acid was a HLA DNA fragment generated by amplifying a 231-base pair segment of HLA DQb gene using primers flanking a hypervariable region located in Exon 1.
  • the HLA DNA fragment was isolated from the cell line FPF (Human Genetic Mutant Cell Deposit, Camden, New Jersey) as described by Maniatis and others, Molecular Cloning, A Laboratory Manual , page 458, Cold Spring Harbor Laboratory, New York, 1982.
  • the primers used in amplification in the assay had the following sequences: and wherein Y represents a biotintetraethylene glycol linker moiety attached to the oligonucleotide using the procedure described in US-A-4,914,210.
  • the secondary oligonucleotides used in the practice of this invention had the following sequences: All of the oligonucleotides used in these examples were prepared and purified using a conventional automated SAM-1 DNA synthesizer (Biosearch) and known procedures (for example, as described by Beaucage and others, Tetrahedron Letters , 22, 1859-1862, 1981).
  • An amplified target nucleic acid was provided by amplifying the noted HLA DNA fragment using tritiated dNTP's in the following manner:
  • the HLA DNA fragment (1 mg) was added to a buffer solution (100 ml) containing tris(hydroxymethyl)aminomethane hydrochloride buffer (67 mmolar, pH 8.8), ammonium sulfate (16.6 mmolar), magnesium chloride (2.5 mmolar) and gelatin (10 mg).
  • the primers described above were added (20 pmoles of each) followed by the tritiated dNTP's (0.17 mmolar of each), and the DNA polymerase (12 units).
  • a solution (10 ml) of the resulting amplified target nucleic acid was heated to 95°C for five minutes to denature the strands of nucleic acid, then mixed separately with the following components:
  • Each of the resulting suspensions were in a buffered solution containing sodium phosphate (0.125 molar, pH 6.8), sodium chloride (2.5 molar) and ethylenediaminetetraacetic acid (1 mmolar). They were incubated at 42°C for 10 minutes to allow the capture and secondary oligonucleotides to hybridize to the amplified target nucleic acid.
  • the hybridized products were washed with a solution (300 ml) containing sodium phosphate (0.85 mmolar), sodium chloride (15 mmolar) and sodium dodecyl sulfate (0.5%) which had been prewarmed to 50°C.
  • the resulting suspensions were centrifuged, and the supernatants decanted. The amount of tritium label remaining in the water-insoluble product was measured for all assays. The results are shown in Table I below.
  • a separate set of suspensions containing the hybridized products of capture probe, secondary oligonucleotides and amplified target nucleic acid were detected using colorimetric signals in SURECELLTM disposable test devices (Eastman Kodak Company). These devices contained three test wells having a LOPRODYNETM microporous membrane (1.2 mmeter average pore size, Pall Corp.) in each test well. The suspensions were added to the test devices and fluid was allowed to flow through the membranes while retaining the hybridized products on the membranes.
  • the avidin-horseradish peroxidase conjugate (30 ml of solution containing 2.3 ng of conjugate) was added to the test wells, and the SURECELLTM test devices were incubated at room temperature for 2 minutes. The products were then washed with a solution (200 ml) containing tris(hydroxymethyl)aminomethane (50 mmolar, pH 8.8), sodium dodecyl sulfate (2.4%), sodium chloride (0.5 molar) and 1-methyl-2-pyrrolidinone (0.25 mmolar). The leuco dye solution (50 ml) was added, followed by incubation for 5 minutes at room temperature. The dye signal on the membranes was visually evaluated and scored against a color chart (scores of 0 to 10 with 10 representing highest dye density). The results are shown in Table I below.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Claims (10)

  1. Verfahren zur Amplifikation und zum Nachweis einer doppelsträngigen Nucleinsäure, umfassend:
    A. nach Denaturierung einer doppelsträngigen Zielnucleinsäure und unter Hybridisierungsbedingungen das Amplifizieren der Zielnucleinsäure unter Verwendung einer thermostabilen DNA-Polymerase, komplementärer Primer und dNTPs,
    B. das Bilden eines wasserunlöslichen Hybridisierungsprodukts der amplifizierten Zielnucleinsäure mit einer wasserunlöslichen, nicht nachweisbar markierten Abfangsonde, wobei die Abfangsonde ein wasserunlösliches polymeres Teilchen umfaßt, an das kovalent ein zu einer ersten Sequenz der Zielnucleinsäure komplementäres Oligonucleotid gebunden ist, wobei das Oligonucleotid eine Länge von 15-20 Nucleotiden aufweist, und
    gleichzeitig oder vor der Produktbildung das Kontaktieren der amplifizierten Zielnucleinsäure mit einem oder mehreren, wasserlöslichen, gesonderten sekundären Oligonucleotiden, wobei die einzelnen sekundären Oligonucleotide zu einer Sequenz der Zielnucleinsäure, die von der ersten Sequenz abweicht, komplementär sind und wobei die sekundären Oligonucleotide eine Länge aufweisen, die gleich oder größer als die Länge des Abfangsonden-Oligonucleotids ist,
    um die sekundären Oligonucleotide mit der amplifizierten Zielnucleinsäure zu hybridisieren, und
    C. das Nachweisen des erhaltenen hybridisierten Produkts der Zielnucleinsäure mit der Abfangsonde, umfassend die Verwendung einer Nachweissonde, die komplementär ist zu einer Sequenz der Zielnucleinsäure, die von den zur Abfangsonde und den sekundären Oligonucleotiden komplementären Sequenzen abweicht, oder die Verwendung einer Nachweissonde, die zu mindestens einem der sekundären Oligonucleotide komplementär ist oder die Verwendung von markierten Primern oder die Verwendung von markierten dNTPs.
  2. Verfahren nach Anspruch 1 zum Nachweis von einem beliebigen der Bestandteile humane Leucozyten-Antigen-DNA, HIV-I-DNA, HIV-II-DNA, zytomegalovirale DNA, humane papillomavirale DNA oder β-Globin-DNA oder ein Fragment davon.
  3. Verfahren nach einem der Ansprüche 1 und 2, wobei die Zielnucleinsäure gleichzeitig mit der Abfangsonde und den sekundären Oligonucleotiden kontaktiert wird.
  4. Verfahren nach einem der Ansprüche 1 bis 3, wobei die Konzentration der sekundären Oligonucleotide die gleiche wie die des Abfangsonden-Oligonucleotids ist.
  5. Verfahren nach einem der Ansprüche 1 bis 4, wobei die einzelnen Hybridisierungen bei einer Temperatur von 40-45°C für mindestens 5 Minuten durchgeführt wird.
  6. Verfahren nach einem der Ansprüche 1 bis 5, wobei die Zielnucleinsäure eine Länge von weniger als 250-mer aufweist.
  7. Verfahren nach einem der Ansprüche 1 bis 6, wobei die Amplifikation unter Verwendung einer thermostabilen DNA-Polymerase, die aus einer Thermus-Spezies isoliert ist, oder eines rekombinanten Äquivalents davon und unter mindestens 20 Amplifikationszyklen erreicht wird.
  8. Verfahren nach einem der Ansprüche 1 bis 7, wobei die Abfangsonde an einem Substrat immobilisiert ist, das aus der Gruppe mikroporöse Filtrationsmembranen, polymere Filme und harzbeschichtete Papiere ausgewählt ist und wobei der Nachweis des hybridisierten Produkts am Substrat erfolgt.
  9. Kit zur Amplifikation und zum Nachweis einer Zielnucleinsäure nach dem Verfahren von Anspruch 1, umfassend eine Sonde mit einem zu einer ersten Sequenz der Zielnucleinsäure komplementären Oligonucleotid und ein oder mehr wasserlösliche, gesonderte sekundäre Oligonucleotide, wobei die sekundären Oligonucleotide jeweils komplementär zu einer Sequenz der Zielnucleinsäure, die von der ersten Sequenz abweicht, sind,
    wobei das Kit dadurch gekennzeichnet ist, daß es sich bei der Sonde um eine wasserunlösliche Abfangsonde handelt, die nicht nachweisbar markiert ist und ein wasserunlösliches polymeres Teilchen enthält, an das das Sondenoligonucleotid gebunden ist, wobei das Oligonucleotid eine Länge von 15-20 Nucleotiden aufweist, und
    wobei die sekundären Oligonucleotide jeweils eine Länge aufweisen, die gleich oder größer als die Länge des Abfangsonden-Oligonucleotids ist.
  10. Kit nach Anspruch 9, wobei das Abfangsonden-Oligonucleotid 15-mer bis 20-mer ist und die sekundären Oligonucleotide jeweils unabhängig 15-mer bis 35-mer sind.
EP92203000A 1991-10-02 1992-09-30 Nachweis von amplifizierten Nukleinsäuren unter Verwendung von sekundären wasserlöschlichen Helper-Oligonukleotiden und Testsatz dafür Expired - Lifetime EP0546590B1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/769,624 US5387510A (en) 1991-10-02 1991-10-02 Detection of amplified nucleic acid using secondary capture oligonucleotides and test kit
US769624 1991-10-02

Publications (2)

Publication Number Publication Date
EP0546590A1 EP0546590A1 (de) 1993-06-16
EP0546590B1 true EP0546590B1 (de) 1997-02-26

Family

ID=25086024

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92203000A Expired - Lifetime EP0546590B1 (de) 1991-10-02 1992-09-30 Nachweis von amplifizierten Nukleinsäuren unter Verwendung von sekundären wasserlöschlichen Helper-Oligonukleotiden und Testsatz dafür

Country Status (7)

Country Link
US (1) US5387510A (de)
EP (1) EP0546590B1 (de)
JP (1) JP3497518B2 (de)
CA (1) CA2075683A1 (de)
DE (1) DE69217623T2 (de)
HK (1) HK1000253A1 (de)
SG (1) SG87728A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5610274A (en) * 1991-11-20 1997-03-11 Cpg, Inc. Production and use of magnetic porous inorganic materials
US6767510B1 (en) * 1992-05-21 2004-07-27 Biosite, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
US7524456B1 (en) 1992-05-21 2009-04-28 Biosite Incorporated Diagnostic devices for the controlled movement of reagents without membranes
US6905882B2 (en) 1992-05-21 2005-06-14 Biosite, Inc. Diagnostic devices and apparatus for the controlled movement of reagents without membranes
FR2701961B1 (fr) * 1993-02-24 1995-04-21 Bio Merieux Procédé de destabilisation d'une structure secondaire intracaténaire d'un polynucléotide simple brin, et de capture dudit nucléotide.
FR2710075B1 (fr) * 1993-09-15 1995-10-27 Bio Merieux Réactif et procédé pour la détection d'une séquence nucléotidique avec amplification de signal.
US5591580A (en) * 1994-03-31 1997-01-07 Johnson & Johnson Clinical Diagnostics, Inc. Method, test element and test kit for semi-quantitative detection of target nucleic acid
US5834181A (en) * 1994-07-28 1998-11-10 Genzyme Corporation High throughput screening method for sequences or genetic alterations in nucleic acids
CA2163393C (en) * 1994-11-30 2003-04-22 Colleen Marie Nycz Amplification and detection of mycobacteria nucleic acids
US5683875A (en) * 1995-05-04 1997-11-04 Hewlett-Packard Company Method for detecting a target nucleic acid analyte in a sample
AU744032B2 (en) * 1995-06-07 2002-02-14 Bayer Corporation Enhancement of alkaline phosphatase with SDS in chemiluminescent substrates and enzyme inhibition assays
US5989813A (en) * 1995-07-13 1999-11-23 Molecular Innovations, Inc. Detection of amplified nucleic acid sequences using bifunctional haptenization and dyed microparticles
CA2226717A1 (en) * 1995-07-13 1997-01-30 Immunological Associates Of Denver Self-contained device integrating nucleic acid extraction, amplification and detection
US5770365A (en) * 1995-08-25 1998-06-23 Tm Technologies, Inc. Nucleic acid capture moieties
US5811253A (en) * 1995-09-01 1998-09-22 Johnson & Johnson Clinical Diagnostics, Inc. Use of vanadium bromoperoxidase as a signal-generating enzyme for chemiluminescent systems: test kits and analytical methods
GB9620075D0 (en) 1996-09-26 1996-11-13 Dynal As Method
US6110676A (en) * 1996-12-04 2000-08-29 Boston Probes, Inc. Methods for suppressing the binding of detectable probes to non-target sequences in hybridization assays
WO1998037237A1 (en) * 1997-02-21 1998-08-27 Saigene Corporation Compositions and methods for determining predisposition to insulin dependent diabetes mellitus
US6489455B2 (en) 1997-05-21 2002-12-03 Clontech Laboratories, Inc. Methods of assaying differential expression
US5994076A (en) * 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
US6962778B1 (en) 1997-09-25 2005-11-08 Boston Probes, Inc. Methods, kits and compositions for suppressing the binding of detectable probes to non-target sequences in hybridization assays
ES2524048T3 (es) 2003-03-31 2014-12-03 F. Hoffmann-La Roche Ag Composiciones y métodos para la detección de ciertos flavivirus, incluidos los miembros del serogrupo del virus de la encefalitis japonesa
US7381811B2 (en) 2003-05-19 2008-06-03 Gen-Probe Incorporated Compositions and methods for detecting Trichomonas vaginalis in a sample
EP1784508B1 (de) * 2004-08-09 2012-10-03 Generation Biotech, LLC Verfahren zur isolierung und amplifikation von nukleinsäuren
CN103418295B (zh) 2007-06-21 2015-11-18 简.探针公司 用于混合检测腔室的内容物的仪器和方法
JP5670194B2 (ja) * 2007-10-09 2015-02-18 ユニヴァーシティー オブ ノートル ダム デュ ラック 多種類の標的を検出するためのマイクロ流体プラットフォーム
CA2787327C (en) 2010-01-22 2015-09-15 Damon Kittredge Getman Probes for detecting the presence of trichomonas vaginalis in a sample
CN104302783B (zh) 2012-02-09 2018-02-09 生命技术公司 缀合的聚合物颗粒及其制备方法
US10144968B2 (en) 2015-07-02 2018-12-04 Life Technologies Corporation Conjugation of carboxyl functional hydrophilic beads
CN108350490B (zh) 2015-07-06 2022-06-21 生命技术公司 用于测序的底物和方法
CA3108105A1 (en) 2018-08-08 2020-02-13 Gen-Probe Incorporated Compositions, methods and kits for detecting mycoplasma genitalium
EP4018004A1 (de) 2019-08-23 2022-06-29 Gen-Probe Incorporated Zusammensetzungen, verfahren und kits zum nachweis von treponema pallidum

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4755458A (en) * 1984-08-30 1988-07-05 Enzo Biochem, Inc. Composition and method for the detection of the presence of a polynucleotide sequence of interest
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US5079351A (en) * 1986-11-26 1992-01-07 Cetus Corporation Oligonucleotides and kits for detection of htlvi and htlvii viruses by hybridization
AU622104B2 (en) * 1987-03-11 1992-04-02 Sangtec Molecular Diagnostics Ab Method of assaying of nucleic acids, a reagent combination and kit therefore
US5030557A (en) * 1987-11-24 1991-07-09 Ml Technology Venture Means and method for enhancing nucleic acid hybridization

Also Published As

Publication number Publication date
JPH05211899A (ja) 1993-08-24
HK1000253A1 (en) 1998-02-13
DE69217623T2 (de) 1998-01-02
SG87728A1 (en) 2002-04-16
EP0546590A1 (de) 1993-06-16
CA2075683A1 (en) 1993-04-03
DE69217623D1 (de) 1997-04-03
JP3497518B2 (ja) 2004-02-16
US5387510A (en) 1995-02-07

Similar Documents

Publication Publication Date Title
EP0546590B1 (de) Nachweis von amplifizierten Nukleinsäuren unter Verwendung von sekundären wasserlöschlichen Helper-Oligonukleotiden und Testsatz dafür
US5514550A (en) Nucleic acid test article and its use to detect a predetermined nucleic acid
EP0408738B1 (de) Nukleinsäureprüfungswerkstoff und seine anwendung für die detektion einer vorausbestimmten nukleinsäure
EP0592035B1 (de) Thermostabile DNA-Polymerase-Zusammensetzung die ein Temparatur-Inhibitor enthält, diagnostische Testkits und die Verwendung
JP3802110B2 (ja) 核酸の同時増幅方法並びにそのための組成物、試験キット及び試験装置
US6475729B1 (en) Nucleic acid amplification and detection methods using rapid polymerase chain reaction cycle
US5733751A (en) Diagnostic compositions, elements, methods and test kits for amplification and detection of two or more DNA's using primers having matched melting temperatures
EP0439222B1 (de) Wasserunlösbares Reagenz, Nukleinsäure-Sonde, Testsatz und Verfahren zur Diagnose und Isolierung
US5403707A (en) Diagnostic compositions, elements, methods and test kits for amplification and detection of retroviral DNA using primers having matched melting temperatures
EP0370694A2 (de) Diagnosesatz und Verfahren zum Nachweis von Nukleinsäuren unter Verwendung einer Festphase
EP0648845B1 (de) Verfahren zur Koamplifikation zweier unterschiedlicher Nukleinsäure-Sequenzen unter Verwendung der Polymerase-Kettenreaktion
EP0630973A2 (de) Diagnosezusammensetzungen, Elemente, Verfahren und Testkits zur Amplifikation und zum Nachweis von zwei oder mehren DNS und Verwendung von Primern mit angepassten Schmelztemperaturen
IE910210A1 (en) Method and kits for detecting human leukocyte antigen dna
EP0388171B1 (de) Verfahren zur Reinigung, Vervielfachung und zum Nachweis einer Nukleinsäure
CA2145957C (en) Method, test element and kit for semi-quantitative detection of target nucleic acid
EP0694617B1 (de) Verfahren zur Amplifikation mit zwischenliegendem Renaturierungsschritt
EP0586011A2 (de) Verfahren zur Herstellung und Amplifikation von Nukleinsäuren
CA2024978A1 (en) Nucleic acid detection method using unequal primer concentrations in polymerase chain reaction

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE FR GB LI SE

17P Request for examination filed

Effective date: 19931108

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: CLINICAL DIAGNOSTIC SYSTEMS, INC.

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC.

17Q First examination report despatched

Effective date: 19950922

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): CH DE FR GB LI SE

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: E. BLUM & CO. PATENTANWAELTE

Ref country code: CH

Ref legal event code: EP

REF Corresponds to:

Ref document number: 69217623

Country of ref document: DE

Date of ref document: 19970403

ET Fr: translation filed
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19970526

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC.

Free format text: JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC.#100 INDIGO CREEK DRIVE#ROCHESTER NEW YORK 14650 (US) -TRANSFER TO- JOHNSON & JOHNSON CLINICAL DIAGNOSTICS, INC.#100 INDIGO CREEK DRIVE#ROCHESTER NEW YORK 14650 (US)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20100914

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20100921

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20100929

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20100922

Year of fee payment: 19

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20110930

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20120531

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 69217623

Country of ref document: DE

Effective date: 20120403

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110930

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20120403

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110930

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110930